PlainRecalls
FDA Drug Moderate Class II Terminated

Teva Hydroxyzine Pamoate Capsules, USP, 25 mg, 100- count bottle, Rx Only,Distributed by Teva Pharmaceuticals, USA, Sellersville, PA. NDC 0555-0323-02.

Reported: March 12, 2014 Initiated: January 24, 2014 #D-1095-2014

Product Description

Teva Hydroxyzine Pamoate Capsules, USP, 25 mg, 100- count bottle, Rx Only,Distributed by Teva Pharmaceuticals, USA, Sellersville, PA. NDC 0555-0323-02.

Reason for Recall

CGMP Deviations: Hydroxyzine Pamoate Capsules, USP, 25 mg were manufactured using an unapproved material: API was incorrectly released for use in manufacturing.

Details

Recalling Firm
Teva Pharmaceuticals USA
Units Affected
35746 capsules
Distribution
Nationwide.
Location
Horsham, PA

Frequently Asked Questions

What product was recalled?
Teva Hydroxyzine Pamoate Capsules, USP, 25 mg, 100- count bottle, Rx Only,Distributed by Teva Pharmaceuticals, USA, Sellersville, PA. NDC 0555-0323-02.. Recalled by Teva Pharmaceuticals USA. Units affected: 35746 capsules.
Why was this product recalled?
CGMP Deviations: Hydroxyzine Pamoate Capsules, USP, 25 mg were manufactured using an unapproved material: API was incorrectly released for use in manufacturing.
Which agency issued this recall?
This recall was issued by the FDA Drug on March 12, 2014. Severity: Moderate. Recall number: D-1095-2014.